Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Date:12/11/2012

n spread to other tissues, such as bone marrow and liver. In the United States, there are approximately 70,130 new cases of NHL and 4,600 new cases of MCL each year.

About Ibrutinib

Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating B-cell apoptosis, cell adhesion, and lymphocyte migration and homing. Through these multiple actions, BTK helps to direct malignant B cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The clinical development program includes 23 clinical trials – six Phase 3, nine Phase 2, one Phase 1/2, and seven Phase 1 trials currently underway.

About the Janssen and Pharmacyclics Collaboration

Janssen Biotech, Inc. and Pharmacyclics Inc. entered into a worldwide collaboration on December 8, 2011, to develop and commercialize ibrutinib. Following regulatory approval, Janssen and Pharmacyclics will co-commercialize ibrutinib. In the United States, both companies will share in commercialization activities; outside the United States, Janssen will lead and perform commercialization activities. Each company is leading development for specific indications.

About Janssen Research & Development, LLC

Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
2. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
3. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
6. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
11. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... and BOSTON , September 16, 2014 ... Scientific Officer, Fiona Marshall , will give a presentation ... protein-coupled receptors using StaR ®   technology ... in Drug Discovery and Development " virtual symposium run by ... Society. The virtual symposium is on Wednesday, 24 September 2014; ...
(Date:9/15/2014)... , Sept. 16, 2014 The French ... (HNF) announced today an agreement to collaborate on programs ... support the development of a stronger CMT patient and ... support to several HNF,s initiatives including: , ... the HNF website featuring  HNF newsletters, materials and latest ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Nov. 5, 2010 EnVivo Pharmaceuticals today announced it ... agonist, possesses a novel mechanism not previously seen in ... Acetylcholine (ACh) to enhance cognition. By acting ... makes it possible for smaller amounts of naturally occurring ...
... Nov. 5, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... the three and nine months ended September 30, 2010. ... U.S. Food and Drug Administration (FDA) approved OFIRMEV™ (acetaminophen) ...
Cached Medicine Technology:EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 2Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 4Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 5Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 6
(Date:9/16/2014)... QuickMedical, a national leader in the ... veteran-owned small business has officially launched three new ... Nipro Medical, and CP Medical Sutures. , ... best, most affordable medical equipment and supplies. To ... effort to reach new medical facilities, QuickMedical has ...
(Date:9/16/2014)... Richmond, VA (PRWEB) September 16, 2014 ... Museum of Virginia this fall. Reflecting on what it ... Ethics: Expanding Community Vision investigates unique and thought-provoking topics. ... people to be inspired to look at their world ... provoking and set the stage for truly enlightening dialogue,” ...
(Date:9/16/2014)... Today, the Diamond in the Raw Foundation ... held, Sunday, October 19, 2014 at the Skirball Cultural ... show honors the dare-devil stuntwomen of film and television ... Over 12 categories will be recognized in the two-hour ... , Special honors will be given to legendary stuntwomen ...
(Date:9/16/2014)... N.C. (PRWEB) September 16, 2014 Triad ... President & CEO of Intersil and former President of ... of directors. , “David has extraordinary technology and business ... Triad’s board of directors,” said Lynn Hayden, Triad CEO ... years of analog and mixed signal semiconductor experience to ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 A peep-toe ... back, bootie, or any other dress shoe) in which ... the toes to show. Peep-toe shoes were popular beginning ... shoes had a brief resurgence in the 1970s/80s, before ... they have enjoyed some popularity again, with variations such ...
Breaking Medicine News(10 mins):Health News:Expanding Community Vision at the Science Museum of Virginia 2Health News:Hollywood's Action Icon Awards to Honor Legendary Stuntwomen In A Star-Studded Gala and Awards Ceremony 2Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:Nice Peep Toes Are For Sale At Fecbek.com 2
... THURSDAY, Dec. 15 (HealthDay News) -- Lack of time is ... suggests that several short intensive workouts a week may help ... regimens. The small, new study found that 30 ... time of 75 minutes a week with warm-up and cool-down ...
... -- Nearly 20 million Americans who see a dentist at ... general health care provider, which suggests that dentists could screen ... pressure, diabetes and heart disease, a new study says. ... adults who took part in the 2008 U.S. National Health ...
... , THURSDAY, Dec. 15 (HealthDay News) - To catch cervical ... human papillomavirus (HPV) test is the best option for women ... with the more traditional Pap smear resulted in earlier detection ... developing, said study author Dr. Chris Meijer, a professor of ...
... researchers at the University of Alberta have discovered a new ... those living with the disease, by using a powerful, triple ... brain tissue. The researchers discovered that iron levels in ... brain that are responsible for relaying messages. High iron levels ...
... coffee maker, and the simple quest becomes, well, an ordeal. After ... you finally make a purchase, only to wonder: "Was this the ... Reality check: Is this you? If so, new research ... to make a decision that you,ll be happy with. Joyce ...
... (HealthDay News) -- Low levels of iron in the blood ... that form in a vein, according to the results of ... vessel disease. The findings suggest that treating iron deficiency ... (DVT), according to the researchers at Imperial College London in ...
Cached Medicine News:Health News:Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds 2Health News:Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds 3Health News:Dentists Could Fill Gap in Health Care, Study Says 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 3Health News:Using powerful MRI to track iron levels in brain could be new way to monitor progression of MS 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 3Health News:Low Iron Levels May Increase Blood Clot Risk 2
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
... Acolytes core technology relates to the ultrasensitive ... found in all living cells. ATP ... using bioluminescence. By coupling AK ... via extraction using antibody-coated beads, Acolyte can ...
... DYONICS POWERMAX Shaver Handpiece has 25% more ... standard Smith & Nephew handpiece providing optimal ... handling and reduced hand fatigue. ,The forward/reverse ... suction lever are all co-located to allow ...
... tailored to individual needs. The pump can ... Indeed a Shaver unit only is featured ... and handpiece.,The REVOLUTION shaver system features a ... progressive motor (up to 4.000 rpm). When ...
Medicine Products: